Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS: PVCT · Delayed Price · USD
0.137
+0.003 (2.11%)
May 30, 2023, 3:58 PM EDT - Market closed
PVCT Market Cap
PVCT has a market cap or net worth of $55.65 million as of June 1, 2023. Its market cap has increased by 132.86% in one year.
Market Cap
55.65M
Enterprise Value
58.26M
1-Year Change
132.86%
Ranking
n/a
Category
Stock Price
$0.14
Market Cap Chart
Since March 30, 2006, PVCT's market cap has increased from $38.70M to $55.65M, an increase of 43.81%. That is a compound annual growth rate of 2.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 30, 2023 | 57.50M | 2.31% |
| May 26, 2023 | 56.20M | 1.44% |
| May 25, 2023 | 55.40M | -0.72% |
| May 24, 2023 | 55.80M | -4.29% |
| May 23, 2023 | 58.30M | -1.35% |
| May 22, 2023 | 59.10M | -0.84% |
| May 19, 2023 | 59.60M | 0.85% |
| May 18, 2023 | 59.10M | 0.68% |
| May 17, 2023 | 58.70M | 3.71% |
| May 16, 2023 | 56.60M | -3.58% |
| May 15, 2023 | 58.70M | -2.17% |
| May 12, 2023 | 60.00M | 2.21% |
| May 11, 2023 | 58.70M | -1.51% |
| May 10, 2023 | 59.60M | 2.94% |
| May 9, 2023 | 57.90M | -0.69% |
| May 8, 2023 | 58.30M | -1.35% |
| May 5, 2023 | 59.10M | 3.50% |
| May 4, 2023 | 57.10M | 9.81% |
| May 3, 2023 | 52.00M | -4.59% |
| May 2, 2023 | 54.50M | -9.77% |
| May 1, 2023 | 60.40M | 7.47% |
| Apr 28, 2023 | 56.20M | -3.60% |
| Apr 27, 2023 | 58.30M | 0.69% |
| Apr 26, 2023 | 57.90M | -1.36% |
| Apr 25, 2023 | 58.70M | 1.38% |
View and export this data all the way back to 2006.
Start Free Trial.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Cerevel Therapeutics Holdings, Inc. | 5.11B |
| Celldex Therapeutics, Inc. | 1.50B |
| Crinetics Pharmaceuticals, Inc. | 1.18B |
| Kiniksa Pharmaceuticals, Ltd. | 968.81M |
| Aerovate Therapeutics, Inc. | 405.01M |
| Mineralys Therapeutics, Inc. | 354.38M |
| Scholar Rock Holding Corporation | 315.98M |
| NGM Biopharmaceuticals, Inc. | 249.55M |
| Ikena Oncology, Inc. | 233.94M |
| Nkarta, Inc. | 226.08M |
| Kezar Life Sciences, Inc. | 201.29M |
| Century Therapeutics, Inc. | 189.47M |
| Vaccitech plc | 93.62M |
| Xilio Therapeutics, Inc. | 83.69M |
| Acurx Pharmaceuticals, Inc. | 38.05M |
| Protara Therapeutics, Inc. | 31.55M |
| Axcella Health Inc. | 28.87M |
| Cyclacel Pharmaceuticals, Inc. | 8.03M |
| NeuBase Therapeutics, Inc. | 6.02M |